About Amazentis
Amazentis is a company based in Lausanne (Switzerland) founded in 2007. Amazentis has raised $8.9 million across 2 funding rounds from investors including Nestlé Health Science. Amazentis offers products and services including Mitopure Softgels, The Day Cream, Mitopure Powder, The Night Cream, and The Serum. Amazentis operates in a competitive market with competitors including DecodeAge, Biote, Timeline, Ponce De Leon Health and Nuchido, among others.
- Headquarter Lausanne, Switzerland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Jurisdiction Bangalore North, Karnataka, India
-
Annual Revenue
$403.09 K (USD)19.31as on Mar 31, 2022
-
Net Profit
$26.11 K (USD)-14.87as on Mar 31, 2022
-
EBITDA
$31.2 K (USD)28.43as on Mar 31, 2022
-
Total Equity Funding
$8.9 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Amazentis
Amazentis offers a comprehensive portfolio of products and services, including Mitopure Softgels, The Day Cream, Mitopure Powder, The Night Cream, and The Serum.
Dietary supplement for cellular energy and health support.
Cream that strengthens skin barrier and reduces aging signs.
Powder for daily health routine and mitochondrial benefits.
Cream for skin regeneration and resilience overnight.
Serum that lifts and firms skin with Urolithin A.
People of Amazentis
Unlock access to complete
Sales and Marketing
9 people
Leadership Team
6 people
Software Development Team
4 people
Creative and Marketing Team
3 people
Senior Team
1 people
Customer Team
1 people
Human Resources and Administration
1 people
Data Analysis and Operations Team
1 people
Unlock access to complete
Funding Insights of Amazentis
Amazentis has successfully raised a total of $8.9M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Amazentis
Amazentis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Nestlé Health Science.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Nutritional dietary supplements are provided for health and wellness needs.
|
Locked | Locked | Locked |
Investor details for Amazentis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Amazentis
Investment portfolio details for Amazentis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Amazentis
Detailed financials for Amazentis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Amazentis Comparisons
Peer comparison for Amazentis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Amazentis
Amazentis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DecodeAge, Biote, Timeline, Ponce De Leon Health and Nuchido, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Online platform offering drugs for longevity and age health
|
|
| Locked | Locked | Locked |
Hormone replacement and pellet therapy services are offered.
|
|
| Locked | Locked | Locked |
Clinically-tested Urolithin A supplements and skincare are developed.
|
|
| Locked | Locked | Locked |
Anti-aging nutraceutical supplements are developed and tested.
|
|
| Locked | Locked | Locked |
Manufacturer of dietary supplements
|
Detailed competitors of Amazentis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Amazentis
Complete news archive for Amazentis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amazentis
Amazentis was founded in 2007 and raised its 1st funding round 11 years after it was founded.
Amazentis is headquartered in Lausanne, Switzerland. It is registered at Lausanne, Vaud, Switzerland.
Amazentis is a funded company, having raised a total of $8.9M across 2 funding rounds to date.
Annual revenue of Amazentis is $403.09K as on Mar 31, 2022.
Amazentis is a biotechnology company based in Switzerland that is developing innovative nutritional products to combat aging and improve the quality of life. Amazentis focus is on harnessing the effects of Urolithin A on aging mitochondria - a finding that the founders reported in a landmark research article in the journal Nature Medicine where they showed that Urolithin A induces mitophagy and prolong life span in nematodes, and improves muscle function in rodents. Urolithin A is produced naturally by human gut bacteria by the conversion of ellagitannins - natural precursor compounds found in, among others, pomegranates. Once taken up by cells, Urolithin A acts by preventing the accumulation of dysfunctional mitochondria in aging cells.
Amazentis offers Mitopure Softgels, The Day Cream, Mitopure Powder, The Night Cream, and The Serum.
Amazentis has 1 investor. Key investors include Nestlé Health Science.